News | December 14, 2023
Venus Remedies expands global presence with marketing authorisation for enoxaparin from Azerbaijan
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
Demonstrate significant bleed reduction in hemophilia A and B
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
NATCO temporarily shut down the operations due to cyclone with flooding/water logging of the factory premises
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Almost 300 million people globally have chronic hepatitis B
Both the India and GCC entities will be operated by separate dedicated management teams
Subscribe To Our Newsletter & Stay Updated
